Background::Although
de novo stage IV breast cancer is so far incurable, it has entered an era of individualized treatment and chronic disease management. Based on systemic treatment, whether the surgical resection of primary or metastatic foci of
de novo stage IV breast cancer can bring survival benefits is currently controversial. We aimed to explore the clinicopathological factors and current status of the management of
de novo stage IV breast cancer in China to provide a reference for clinical decisions.
Methods::Based on the assistance of Chinese Society of Breast Surgery, a retrospective study was conducted to analyze the clinical data of patients with
de novo stage IV breast cancer in 33 centers from January 2017 to December 2018. The relationship between basic characteristic (age, menstrual status, family history, reproductive history, pathological type, estrogen receptor [ER] status, progesterone receptor [PR] status, human epidermal growth factor receptor 2 [HER2] st
作者:Zheng Ang;Guo Bao-Liang;Zhang Jian-Guo;Jin Feng;Chinese Society of Breast Surgery
来源:中华医学杂志英文版 2021 年 134卷 13期